Liquidia faces new patent infringement claim over '327 patent added to PH-ILD suit

Liquidia Corp

United Therapeutics amended complaint adds U.S. Patent No. 11,826,327, issued Nov 28, 2023.
Patent covers inhaled treprostinil for PH-ILD; YUTREPIA label amendment triggers claim.
Liquidia believes no 30-month stay applies because patent issued after original NDA filing.
Case continues in U.S. District Court for Delaware; Liquidia vows vigorous defense.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.